Donga Socio Holdings Asset Resilience Ratio
Donga Socio Holdings asset resilience ratio. Donga Socio Holdings (000640) has an Asset Resilience Ratio of 1.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Donga Socio Holdings (000640) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Donga Socio Holdings (2000–2024)
Asset resilience ratio of Donga Socio Holdings from 2000 to 2024. This chart shows how Donga Socio Holdings's Asset Resilience Ratio has changed over time. Read 000640 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Donga Socio Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Donga Socio Holdings (000640) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩37.95 Billion | 1.85% |
| Total Liquid Assets | ₩37.95 Billion | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Donga Socio Holdings maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Donga Socio Holdings Industry Peers by Asset Resilience Ratio
Compare Donga Socio Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Donga Socio Holdings Asset Resilience Ratio by Year (2000–2024)
Donga Socio Holdings asset resilience ratio by year from 2000 to 2024. The table below shows the annual Asset Resilience Ratio data for Donga Socio Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | ₩9.95 Billion ≈ $6.75 Million |
₩2.03 Trillion ≈ $1.38 Billion |
-1.59pp |
| 2023-12-31 | 2.08% | ₩40.64 Billion ≈ $27.54 Million |
₩1.96 Trillion ≈ $1.33 Billion |
+1.46pp |
| 2022-12-31 | 0.61% | ₩10.63 Billion ≈ $7.20 Million |
₩1.73 Trillion ≈ $1.17 Billion |
-2.86pp |
| 2021-12-31 | 3.48% | ₩58.84 Billion ≈ $39.87 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-0.21pp |
| 2020-12-31 | 3.68% | ₩55.67 Billion ≈ $37.73 Million |
₩1.51 Trillion ≈ $1.02 Billion |
-0.35pp |
| 2019-12-31 | 4.03% | ₩54.81 Billion ≈ $37.14 Million |
₩1.36 Trillion ≈ $920.69 Million |
+3.56pp |
| 2018-12-31 | 0.48% | ₩5.93 Billion ≈ $4.02 Million |
₩1.24 Trillion ≈ $841.64 Million |
+0.40pp |
| 2017-12-31 | 0.08% | ₩1.11 Billion ≈ $749.55K |
₩1.46 Trillion ≈ $989.05 Million |
-0.10pp |
| 2016-12-31 | 0.17% | ₩2.43 Billion ≈ $1.65 Million |
₩1.40 Trillion ≈ $950.26 Million |
-0.13pp |
| 2015-12-31 | 0.30% | ₩3.70 Billion ≈ $2.51 Million |
₩1.22 Trillion ≈ $829.16 Million |
+0.09pp |
| 2014-12-31 | 0.21% | ₩2.25 Billion ≈ $1.52 Million |
₩1.08 Trillion ≈ $732.63 Million |
-0.52pp |
| 2013-12-31 | 0.73% | ₩7.20 Billion ≈ $4.88 Million |
₩988.28 Billion ≈ $669.74 Million |
+0.52pp |
| 2012-12-31 | 0.21% | ₩3.59 Billion ≈ $2.43 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-2.77pp |
| 2011-12-31 | 2.98% | ₩44.45 Billion ≈ $30.12 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.16pp |
| 2010-12-31 | 0.82% | ₩10.09 Billion ≈ $6.84 Million |
₩1.23 Trillion ≈ $836.45 Million |
+0.66pp |
| 2009-12-31 | 0.16% | ₩1.69 Billion ≈ $1.14 Million |
₩1.06 Trillion ≈ $716.50 Million |
-0.43pp |
| 2008-12-31 | 0.59% | ₩4.52 Billion ≈ $3.06 Million |
₩769.94 Billion ≈ $521.78 Million |
-0.37pp |
| 2007-12-31 | 0.96% | ₩6.83 Billion ≈ $4.63 Million |
₩713.72 Billion ≈ $483.68 Million |
+0.05pp |
| 2006-12-31 | 0.91% | ₩6.62 Billion ≈ $4.49 Million |
₩731.74 Billion ≈ $495.89 Million |
-0.35pp |
| 2005-12-31 | 1.25% | ₩9.08 Billion ≈ $6.15 Million |
₩724.29 Billion ≈ $490.84 Million |
+0.04pp |
| 2004-12-31 | 1.21% | ₩8.56 Billion ≈ $5.80 Million |
₩706.01 Billion ≈ $478.45 Million |
-1.10pp |
| 2003-12-31 | 2.31% | ₩15.98 Billion ≈ $10.83 Million |
₩691.41 Billion ≈ $468.56 Million |
+0.08pp |
| 2002-12-31 | 2.23% | ₩13.18 Billion ≈ $8.93 Million |
₩590.72 Billion ≈ $400.32 Million |
-2.21pp |
| 2001-12-31 | 4.44% | ₩26.35 Billion ≈ $17.86 Million |
₩593.63 Billion ≈ $402.30 Million |
+0.49pp |
| 2000-12-31 | 3.95% | ₩21.63 Billion ≈ $14.66 Million |
₩547.36 Billion ≈ $370.94 Million |
-- |
About Donga Socio Holdings
Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of S… Read more